Premarket Biotech Digest – $PTX reports +ve results, $AOLS starts Phase I, $AGEN flunks study

OncoSec Medical Inc. ($ONCS) announced new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec's investigational intratumoral therapy, ImmunoPulse® IL-12, and the approved anti-PD- 1 therapy (pembrolizumab), in patients with unresectable metastatic melanoma. The results ndicated that ImmunoPulse® [...]

By |February 24th, 2017|Digest|0 Comments

Premarket Biotech Digest – $PPHM stock shoots up, $AEMD reports +ve trial results, $HTGM receives delisting notice

Aethlon Medical Inc. ($AEMD) announced the results of its study seeking to validated the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The results validated the ability of the Aethlon Hemopurifier® to capture latent [...]

By |February 23rd, 2017|Digest|2 Comments

Premarket Biotech Digest – $DCTH inks new deal, $HLS reports quarterly results, $ABT announces notes exchange

HealthSouth Corp ($HLS) stock gained over 2 percent in its Tuesday trading session as the company reported its quarterly numbers. Its earnings for the quarter stood at $0.72 per share, beating consensus estimates of $0.63 per share in earnings. The company’s revenue for the [...]

By |February 22nd, 2017|Digest|0 Comments

Cellect Biotechnology reports positive results for ApoGraft trial

Cellect Biotechnology ($APOP) shot up 14 percent in the current trading session as the company announced positive results from its clinical trial of ApoGraft™ in healthy donors. The primary objective for the study was to validate the Company's propriety method of stem cell selection by going through the process of [...]

By |February 21st, 2017|Digest|0 Comments

Premarket Biotech Digest – $VCEL receives FDA nod, $SRPT sells FDA voucher, $TRVN reports +ve results

Premarket Biotech Digest – $VCEL receives FDA nod, $SRPT sells FDA voucher, $TRVN reports +ve results $Digest, $VCEL, $SRPT, $TRVN Sarepta Therapeutics ($SRPT) announced selling an FDA review voucher to Gilead Sciences. The deal is expected to be worth $125 million. The company had [...]

By |February 21st, 2017|Digest|0 Comments

Premarket Biotech Digest – $BSX provides estimates, $PODD reports +ve outcome, $ARQL flunks trial

Momenta Pharmaceuticals ($MNTA) reported a potential hurdle in an application for its Glatopa products. The company said that Sandoz’s contracted fill/finish manufacturing partner, Pfizer, has received an FDA warning letter. The Pfizer facility is a key part of the supply chain for the Company’s [...]

By |February 20th, 2017|Digest|0 Comments

Premarket Biotech Digest – $VRX receives FDA approval, $GLD reports new deal, $XBIT meets endpoints

Gilead Sciences Inc. ($GILD) announced that it has received approval in Canada for its ODEFSEY for treating HIV-1 infection. ODEFSEY is indicated in Canada as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to [...]

By |February 17th, 2017|Digest|0 Comments

Premarket Biotech Digest – $PLX provides updates, $MRK stops trial, $IART acquires new business

Our App Is Updated, Install it here Point your mobile browser to this link - https://gonative.io/share/wexpwj Download the APK for Android (Apple doesn't work yet), ignore the warning messages if any, and install it. Intellia Therapeutics ($NTLA) stock slumped over 9 percent in its [...]

By |February 16th, 2017|Digest|0 Comments

Premarket Biotech Digest – $NVAX restarts clinical trial, $AET terminates merger, $IONS gets milestone payment

Our Android App Is Updated, Install it here Point your mobile browser to this link - app Download the APK for Android (Apple doesn't work yet), ignore the warning messages if any, and install it. Aetna Inc. ($AET) announced that its proposed merger with [...]

By |February 15th, 2017|Digest|0 Comments

Premarket Biotech Digest – $ZLTQ to be acquired, $CUTR reports results, $ANTM gets buy rating

Cutera Inc. ($CUTR) reported its fourth quarter and full financial year results. The company reported 26 percent increase in its revenue for the fourth quarter to a record $37.9 million, due primarily to a 45% growth in North American product revenue. This is the [...]

By |February 14th, 2017|Digest|0 Comments

Premarket Biotech Digest – $TEVA reports strong results, $DXCM gets buy rating, $ICPT changes protocol

Inovio Pharmaceuticals Inc. ($INO) announced its new collaboration with ApolloBio Corporation. The new pact deals with providing ApolloBio with with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV), within Greater China [...]

By |February 13th, 2017|Digest|0 Comments

Premarket Biotech Digest – $AMRN restructures. $NVGN receives grant, $ONVO reports Q3 results

TRACON Pharmaceuticals ($TCON) suffered a setback as the company announced the results from a Phase 2 clinical trial assessing lead product candidate TRC105 in recurrent glioblastoma. The study evaluated the effect on three-month progression-free survival (PFS) of TRC105 combined with Roche's Avastin (bevacizumab) compared [...]

By |February 10th, 2017|Digest|0 Comments

Premarket Biotech Digest –$REGN gets court stay, $LFVN reports Q2 results, $LOXO gets buy rating

Diffusion Pharmaceuticals ($DFFN) stock saw a spike in its price as the company announced the data from a Phase 1/2 clinical trial assessing its trans sodium crocetinate (TSC) in newly diagnosed glioblastoma multiforme (GBM) showing a treatment benefit. The data collected from 59 patients [...]

By |February 9th, 2017|Digest|0 Comments

Premarket Biotech Digest – $GILD reports results, $LLY to cut staff, $NBRV gets buy rating

Sanofi ($SNY) announced its fourth quarter net income at $852.2 million. Its net income, adjusted for non-recurring costs, stood at $0.67 per share. The drugmaker posted revenue of $9.56 billion for the same period. For the full financial year, the company’s reported profit stood [...]

By |February 8th, 2017|Digest|0 Comments

Premarket Biotech Digest – $OPXA enters lease agreement, $CLLS receives IND, $CTLT reports Q2 results

Premarket Biotech Digest – $OPXA enters lease agreement, $CLLS receives IND, $CTLT reports Q2 results $Digest, $OPXA, $CLLS, $CTLT Cellectis SA ($CLLS) announced receiving Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1 clinical trials with [...]

By |February 7th, 2017|Digest|0 Comments

Premarket Biotech Digest – $ISR launches pilot study, $BMY flunks trial, $AZN terminates project

Bristol-Myers Squibb ($BMY) announced negative results for its leukemia drug study. The company is collaborating with Innate Pharmaceuticals for this project. Lirilumab failed to beat a placebo in improving patients' leukemia-free survival. This mid-stage trial showed there was no statistically significant difference identified between [...]

By |February 6th, 2017|Digest|0 Comments

Premarket Biotech Digest – $IPCI receives FDA nod, $GEN inks new deal, $AMGN receives buy rating

Benitec Biopharma ($BNTC) announced that it has significant milestone with regard to its ddRNAi technology to treat ocular diseases, particularly with identifying novel viral vectors. The new development will enable the delivery of the gene therapy to the retina via intravitreal injection. Current ocular [...]

By |February 3rd, 2017|Digest|0 Comments

Premarket Biotech Digest – $LCI reports Q2 earnings, $SNY receives FDA approval, $VCL reports implants

Sarepta Therapeutics Inc. ($SRPT) stock stumbled as the company grappled with the consequences of failing reimbursement issues related to Exondys 51. There had been several analyst reports circulating that the reimbursement situation related to this Duchenne muscular dystrophy (DMD) med is dire. The company [...]

By |February 2nd, 2017|Digest|0 Comments

Premarket Biotech Digest – $PTN closes deal, $MDWD reports study results, $TENX announces trial failure

Mediwound Ltd ($MDWD) stock jumped over 9% in Tuesday trading session as the company announced final positive results from the Company’s second Phase 2 clinical trial evaluating EscharEx® for debridement of dead or damaged tissue in chronic and other hard-to-heal wounds. It also reported [...]

By |February 1st, 2017|Digest|0 Comments

Premarket Biotech Digest – $TEVA loses patent, $LLY reports quarterly results, $RIGL announces trial results

Premarket Biotech Digest – $TEVA loses patent, $LLY reports quarterly results, $RIGL announces trial results $Digest, $TEVA,$LLY,$RIGL Mylan NV ($MYL) announced that it is being investigating by the US antitrust authorities for its EpiPen emergency allergy treatment. The company was earlier asked for information [...]

By |January 31st, 2017|Digest|0 Comments
s2Member®